Drug therapies in bronchopulmonary dysplasia: debunking the myths.
Bronchopulmonary dysplasia (BPD), also known as chronic lung disease (CLD), is one of the most challenging complications in premature infants. The incidence of BPD has been increasing over the past two decades in parallel with an improvement in the survival of this population. Furthermore, the clinical characteristics and the natural history of infants affected by BPD have changed considerably, and newer definitions to clarify the term 'BPD' have also evolved since its first description more than four decades ago. Several drug therapies have also evolved, either to manage these infants' respiratory distress syndrome with an aim to prevent BPD or to manage the established condition. Although there is good evidence to support the 'routine' use of some therapies, many other therapies currently used in relation to BPD remain individual- or institution-specific, depending on beliefs and myths that we have adopted. In this article, we discuss the importance of defining BPD more objectively and the support--or lack thereof--for the drug therapies used in relation to BPD.
Tin
Win
W
James Cook University Hospital, Marton Road, Middlesbrough, UK.
Wiswell
Thomas E
TE
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature / Q000502:physiology*; D011247:Pregnancy; D011663:Pulmonary Surfactants / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D000975:Antioxidants; D001993:Bronchodilator Agents; D011663:Pulmonary Surfactants